Back to news

Hims & Hers Health Shares Slide as Investors Weigh Accounting Leadership Change and Ongoing Margin Questions

Investivoq PriceTracker

Hims & Hers Health (HIMS) is down 5.3% today. Here is some analysis on what might have caused this price movement.

Analysis: A single obvious catalyst is hard to pin down, but the most visible fresh development was a new filing detailing a chief accounting officer transition. This could be because investors treated that filing as another reason to stay cautious while the market also continues to weigh profitability, cash flow, and margin pressure tied to the company’s evolving weight-loss mix.

Details:

  • An October 7 filing showed Jonathan Franklin started as chief accounting officer on October 5 and was appointed principal accounting officer effective October 9, alongside the previously disclosed departure of Irene Becklund from that role.
  • The earlier filing from July had already laid out Becklund’s planned resignation effective October 9, with an advisory arrangement running into 2027, so the latest filing mainly completed the transition timeline.
  • An analyst note published October 8 reiterated a Hold rating and a $32 price target, suggesting no near-term upgrade in sentiment even after the stock’s recent pullback.
  • Recent commentary on the business has highlighted that, while growth remains strong, gross profit mix and cash flow have been areas investors are still monitoring closely, which may have made the shares more sensitive to any incremental uncertainty.

    • Sources:

    SEC, SEC, StreetInsider, Zacks

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $HIMS Insider Trading Activity

    HIMS Insider Trades

    $HIMS insiders have traded $HIMS stock on the open market 27 times in the past 6 months. Of those trades, 1 have been purchases and 26 have been sales.

    Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

    • OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 13 sales selling 228,344 shares for an estimated $6,987,982.
    • SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 5 sales selling 47,729 shares for an estimated $1,348,355.
    • DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
    • MOHAMED ELSHENAWY (CTO) has made 0 purchases and 2 sales selling 37,994 shares for an estimated $1,172,074.
    • MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 28,054 shares for an estimated $840,077.
    • PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,726 shares for an estimated $830,410
    • DEBORAH M. AUTOR (Chief Policy Officer) sold 16,773 shares for an estimated $467,128
    • IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 12,063 shares for an estimated $370,518.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive HIMS Data Alerts
    Get market-moving data, filings, and signals for HIMS in real time.
    Sign Up

    $HIMS Hedge Fund Activity

    We have seen 301 institutional investors add shares of $HIMS stock to their portfolio, and 191 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DEFIANCE ETFS, LLC removed 7,424,258 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $257,399,024
    • DIVISADERO STREET CAPITAL MANAGEMENT, LP added 5,539,672 shares (+1179.1%) to their portfolio in Q2 2026, for an estimated $192,060,428
    • JPMORGAN CHASE & CO added 4,766,781 shares (+inf%) to their portfolio in Q2 2026, for an estimated $165,264,297
    • FMR LLC added 4,230,022 shares (+4535.2%) to their portfolio in Q2 2026, for an estimated $146,654,862
    • MARSHALL WACE, LLP added 3,493,540 shares (+482.4%) to their portfolio in Q2 2026, for an estimated $121,121,031
    • GOLDMAN SACHS GROUP INC added 2,719,170 shares (+110.8%) to their portfolio in Q2 2026, for an estimated $94,273,623
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,453,787 shares (+inf%) to their portfolio in Q2 2026, for an estimated $85,072,795

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $HIMS Price Targets

    Multiple analysts have issued price targets for $HIMS recently. We have seen 7 analysts offer price targets for $HIMS in the last 6 months, with a median target of $35.0.

    Here are some recent targets:

    • Allen Lutz from B of A Securities set a target price of $37.0 on 07/09/2026
    • Maria Ripps from Canaccord Genuity set a target price of $40.0 on 07/01/2026
    • Glen Santangelo from Barclays set a target price of $39.0 on 06/18/2026
    • Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
    • Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
    • Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
    • Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.